Lenacapavir, a new injectable drug for HIV prevention, has been hailed by experts at Emory University as a breakthrough in the fight against the virus. The long-acting treatment offers a solution to adherence challenges faced by many individuals who struggle to take daily oral PrEP (pre-exposure prophylaxis) like Truvada.
The study found lenacapavir to be 96% effective in preventing HIV, with no reported adverse side effects from one participant who received the treatment. Latonia Wilkins, a single mother and social worker participating in clinical trials, has been taking oral HIV preventatives since 2019 but struggled to stay consistent due to her demanding lifestyle.
Lenacapavir’s injectable format could be a game-changer for individuals like Wilkins, who requires frequent attention from family members. With only one injection every six months, the treatment may help improve adherence rates and reduce the risk of HIV transmission.
Experts emphasize the potential impact of lenacapavir on reducing the HIV epidemic. Dr. Valeria Cantos, an associate professor at Emory’s School of Medicine, noted that the treatment is highly effective, safe, and longer-acting than existing options. She also highlighted the importance of equitable distribution and Medicaid expansion to ensure affordability.
With commercial availability expected in 2025 pending FDA approval, advocates are calling for policy changes to make lenacapavir accessible to those who need it most. The treatment’s potential to improve HIV prevention rates is significant, particularly for individuals who face challenges in taking daily oral medications like Truvada.
Source: https://www.fox5atlanta.com/news/injectable-hiv-preventative-lenacapavir-touted-breakthrough-emory-experts